AegirBio
AegirBio AB is a Swedish diagnostics company focused on developing innovative home testing solutions for oral health, therapeutic drug monitoring, and infectious diseases. The company has established a platform that enhances lateral flow tests, significantly improving their sensitivity and precision compared to traditional methods. AegirBio's product lineup includes the Veritope technology, which measures intact natalizumab for multiple sclerosis, alongside the MagniaReader, designed for both research and veterinary use. Their advancements enable robust, affordable, and easy-to-use testing instruments applicable across human health, veterinary, food safety, and environmental sectors. By leveraging novel techniques, AegirBio aims to expand the market for lateral flow tests and enhance patient care through more reliable diagnostics.
Top Regions
Top Stages
1 past transactions
Viraspec
Acquisition in 2020
Viraspec AB is a diagnostics company based in Lund, Sweden, founded in 2020. It specializes in the development and commercialization of rapid diagnostic tests for COVID-19. The company focuses on point-of-care testing, utilizing a robust platform that analyzes blood and saliva samples for the presence of antibodies and the virus itself. Viraspec's innovative test device includes a blood collector and an indicator, facilitating the collection of samples and providing results directly on the device. This approach enables patients to obtain faster, more accurate, and cost-effective diagnostic results, thereby enhancing the fight against COVID-19. As of September 2020, Viraspec operates as a subsidiary of AegirBio AB.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.